Striking results were achieved in a mouse model of pancreatic ductal adenocarcinoma: while PD-1 blockade failed to induce durable anti-responses, combination anti-PD-1/OX40 therapy resulted in total tumor regression in treated mice [66]. Here, TNFRSF4 is linked to neoplasm.